广泛期小细胞肺癌一线化疗进展

Advances on First-line Chemotherapy of Extensive Disease Small-cell Lung Cancer

小细胞肺癌(small cell lung cancer,SCLC)生长迅速,具有高度的侵袭性,就诊时多数患者已发生远处转移,对于广泛期小细胞肺癌,治疗仍以全身化疗为主,在过去30余年里,EP/CE方案作为标准一线化疗方案在治疗广泛期小细胞肺癌中取得了较高的缓解率,但多数患者在化疗停止6个月内疾病发生进展,2年的生存率不足5%,我们需要更加积极有效的一线化疗方案,本文综述了近10余年来广泛期小细胞肺癌的一线化疗进展。

Chemothrapy is the most important treatment for extensive disease small--cell lung cancer （ED--SCLC）, EP/CE regimen leads to a high response rates, but the vast majority of patients will ultimately relapse and die of recurrent disease, this short overall survival time calls for more active treatments. The article will review the advances of the first-- line chemotherapy in the treatment of small--cell lung cancer with extensive disease over the past decade.